Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

He said U.S. losses alone top $500 billion a year and called gene drives “the only scalable” solution. As reported by 24/7 ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Mestastop, a Bengaluru biotech firm, targets cancer metastasis with innovative platforms, preparing for a pivotal phase II ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...